Home HFT to reduce acute exacerbation of COPD; HiFAE trial

During this symposium, Dr. Maxime Patout outlines the current roles of long-term oxygen therapy, home high-flow therapy and non-invasive ventilation to improve the unmet needs of COPD patients. He also presents the protocol of the HiFAE trial.
This is a secured video. To access it for the first time you must fill-in your email address above.

Key facts

  • JIVD CONGRESS 2022
  • WITH DR MAXIME PATOUT
  • HFT TODAY: NEW CLINICAL RESEARCH AND PRACTICE

Content

What do we want for our COPD patients? Dr. Maxime Patout focuses on three important COPD symptoms: dyspnoea, cough and exacerbations, and discusses the roles of long-term oxygen therapy, home high-flow therapy and non-invasive ventilation addressing the symptoms based on current evidence.

Focusing on home high-flow therapy, from the evidence, Dr Patout shows that it can improve dyspnoea1, cough2 and moderate exacerbation rates3-4. But what we don’t know is how high-flow therapy blends with regular therapy and its effect on severe exacerbation. Dr Patout aims to address these two gaps with the HiFAE trial.

“We’re going to see if by giving this treatment to patients that have been admitted with acute severe exacerbation of COPD, we can reduce the subsequent admission for severe exacerbation of COPD.”

Dr Maxime Patout explains the main objective of the HiFAE trial which will compare the use of long-term standard oxygen therapy and home high-flow therapy amongst COPD patients. The main judgement criteria being hospital admissions, survival of AECOPD, or death, as well as several secondary factors including quality of life and lung function, among others.

The trial will start nationwide in France, with the hope of extending it to other European countries. To hear more about this upcoming trial, register now and watch the full symposium.

Speakers

Dr Maxime Patout

Sorbonne Université Faculté de Médecine, France

Looking for more information about high-flow treatment for COPD patients?

Research in home high-flow therapy for COPD

Discover key findings from recent clinical research on the mechanisms of action of home high-flow therapy and the clinical outcomes in patients with COPD.
Learn more

The HiFAE trial

Read more about the new French randomised controlled trial: HiFAE. The main objective of this study is to evaluate the efficacy of home high-flow therapy with oxygen vs standard oxygen therapy for the reduction of acute COPD exacerbations.
Learn more

Home high-flow therapy for COPD

Learn how home high flow therapy could be indicated for domiciliary use in COPD patients experiencing secretion management issues.
Learn more

1. Figarska, S.M., Boezen, H.M. & Vonk, J.M. Dyspnea severity, changes in dyspnea status and mortality in the general population: the Vlagtwedde/Vlaardingen study. Eur J Epidemiol 27, 867–876 (2012). https://doi.org/10.1007/s10654-012-9736-0.

2. Pierre-Régis Burgel, Pascale Nesme-Meyer, Pascal Chanez, Denis Caillaud, Philippe Carré, Thierry Perez, Nicolas Roche, Cough and Sputum Production Are Associated With Frequent Exacerbations and Hospitalizations in COPD Subjects, Chest, Volume 135, Issue 4, 2009, Pages 975-982, ISSN 0012-3692, https://doi.org/10.1378/chest.08-2062.

3. Suissa S, Dell’Aniello S, Ernst PLong-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012;67:957-963.

4. Jacques Piquet, Jean-Michel Chavaillon, Philippe David, Francis Martin, François Blanchon, Nicolas Roche. High-risk patients following hospitalisation for an acute exacerbation of COPD. European Respiratory Journal Oct 2013, 42 (4) 946-955; DOI: 10.1183/09031936.00180312.